进一步提高中西医结合防治肿瘤的临床研究水平  

Further improving research quality in cancer management by integration of traditional Chinese medicine and modern medicine

作　　者：孙燕[1] 

机构地区：[1]中国医学科学院北京协和医学院肿瘤医院,北京100021

出　　处：《中国新药杂志》2011年第17期1588-1591,1611,共5页Chinese Journal of New Drugs

摘　　要：多年来对于中西医能否结合存在争议。近50—60年来,由于中医进入医院,和西医不同学科一样成为重要科室之一,一大批有作为的西医学习中医,因此得到互相认识、交流乃至结合的机会。改革开放以来的30年,政府提出中西医并举,结合的空间扩大,学术环境更自由了,思路也更具体了。世界医学重新重视自然和传统医学。在临床肿瘤学领域内,通过实践已经形成共识:在应用现代医学最大限度地杀灭或抑制肿瘤的同时通过中医调理扶正可以明显提高临床疗效,而且得到广大医师和患者接受和欢迎。而且在应用三氧化二砷静脉注射治疗急性早幼粒白血病(APL),并且发现它的作用机制是调控PML-RARa蛋白诱导凋亡;扶正中药能促进病人的细胞免疫功能已经成为临床医师的共识而且用于临床实践:人参成分之一Rg3作为新生血管抑制剂,和正在进行研究的冬凌草、康莱特、榄香烯等都有望取得进一步的成果。祖国医学在慢性病的调理上具有独特的作用。而调控正是21世纪医学的重要组成部分。靶向治疗本身就是在分子水平上的信息转导的调控,所以从理论上我国学者应当更容易理解"同病异治和异病同治"等原则,这和我们目前的个体化治疗是相通的。当前,我们应当抓住机遇通过中西医结合对世界医学作出我们民族的新贡献。而最大限度地应用现代医学方法开展高水平的临床试验,阐明祖国医学的很多观点,则是一个重要的桥梁。For many years, there have been controversies in the integration of traditional Chinese medicine （TCM） and modern medicine. In recent 5-6 decades, since TCM physicians entered hospitals working with the modern physicians, and excellent Western physicians started to learn TCM, which provided a platform to work together, learn from each others, and exchange ideas and experiences in the management of patients. This has provided possibilities and opportunities of cooperation or integration in the management of same patients. Especially in recent 30 years, the open policy has made it possible to further discuss and even argue with each other, and at the same time, natural medicine and traditional medicine have been recognized as complementary medicine in the world. Consensus has been made in the field of clinical oncology in recent years. For example, at the same time u- sing modern methods to kill or inhibit the cancer cells, TCM can contribute to the protection of host liver, kidney, bone marrow and immune system by modulation activities. It can help patients to recovery and enhance the general condition and immune function, and to reduce the relapse of the diseases after the modern treatment, so that improve the efficacy of treatment and improve the long term survival. Those approaches have been well accepted by the majority of oncologists and patients. The intravenous infusion of As203 has succeeded in the management of APL through modulating PML-RARa protein to induce apoptosis of leukemia cells, which has been well accepted worldwide. Our recent researches, such as using one of the active components Rg3 of gensing as angiogenetic inhibitor, have obtained preliminary clinical results. Oridonine, an active principle isolated from Rabdosia rubesens, has been proved to have inhibitory effects on animal leukemia and esophageal cancer models. Clinical trials show that it is useful in reducing adverse effects of chemotherapy and also in preventing esophageal cancer in patients with esophageal squamous cell hyperpla

关 键 词：中西医结合 临床肿瘤学 慢性病 分子靶向治疗 诊疗个体化 同病异治 异病同治 

分 类 号：R730.53[医药卫生—肿瘤]